New Trial Set to Explore MRD-guided Treatment Escalation in Advanced Melanoma

The first patients have been enrolled in a new Signatera-guided melanoma trial that aims to identify who may need earlier intervention by detecting persistent molecular residual disease (MRD) prior to radiographic progression.